A phase 2 efficacy and safety study of SU011248 [sunitinib] administered in a continuous daily regimen in patients with advanced gastrointestinal stromal tumor

Trial Profile

A phase 2 efficacy and safety study of SU011248 [sunitinib] administered in a continuous daily regimen in patients with advanced gastrointestinal stromal tumor

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2009 Results have been reported in the European Journal of Cancer.
    • 01 Sep 2008 Results presented at the European Society for Medical Oncology.
    • 10 Jun 2008 The expected completion date for this trial is now 1 Jun 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top